Atossa Therapeutics, Inc.
ATOS
$1.88
$0.116.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.58% | 36.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.69% | 23.62% | |||
| Operating Income | 13.69% | -23.62% | |||
| Income Before Tax | 12.33% | -25.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.33% | -25.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.33% | -25.83% | |||
| EBIT | 13.69% | -23.62% | |||
| EBITDA | 13.70% | -23.63% | |||
| EPS Basic | 12.44% | -25.83% | |||
| Normalized Basic EPS | 12.43% | -25.84% | |||
| EPS Diluted | 12.44% | -25.83% | |||
| Normalized Diluted EPS | 12.43% | -25.84% | |||
| Average Basic Shares Outstanding | 0.13% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||